- Home
- OPCH vs OGN Comparison
OPCH vs OGN Comparison
Compare OPCH & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPCH
- OGN
- Stock Information
- Founded
- OPCH N/A
- OGN 1923
- Country
- OPCH United States
- OGN United States
- Employees
- OPCH N/A
- OGN N/A
- Industry
- OPCH Medical/Nursing Services
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- OPCH Health Care
- OGN Health Care
- Exchange
- OPCH Nasdaq
- OGN Nasdaq
- Market Cap
- OPCH N/A
- OGN 4.0B
- IPO Year
- OPCH N/A
- OGN N/A
- Fundamental
- Price
- OPCH $34.79
- OGN $14.73
- Analyst Decision
- OPCH Buy
- OGN Hold
- Analyst Count
- OPCH 7
- OGN 5
- Target Price
- OPCH $33.00
- OGN $20.80
- AVG Volume (30 Days)
- OPCH 1.8M
- OGN 3.8M
- Earning Date
- OPCH 04-29-2025
- OGN 05-01-2025
- Dividend Yield
- OPCH N/A
- OGN 7.61%
- EPS Growth
- OPCH N/A
- OGN N/A
- EPS
- OPCH 1.23
- OGN 3.33
- Revenue
- OPCH $4,998,202,000.00
- OGN $6,403,000,000.00
- Revenue This Year
- OPCH $10.06
- OGN N/A
- Revenue Next Year
- OPCH $8.56
- OGN $0.71
- P/E Ratio
- OPCH $28.33
- OGN $4.42
- Revenue Growth
- OPCH 16.17
- OGN 2.23
- 52 Week Low
- OPCH $21.39
- OGN $13.87
- 52 Week High
- OPCH $35.53
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- OPCH 61.58
- OGN 46.35
- Support Level
- OPCH $34.53
- OGN $14.81
- Resistance Level
- OPCH $35.46
- OGN $14.94
- Average True Range (ATR)
- OPCH 0.66
- OGN 0.52
- MACD
- OPCH -0.07
- OGN -0.08
- Stochastic Oscillator
- OPCH 77.44
- OGN 42.03
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.